Sessions are scheduled in Singapore Time (SGT)
- Jeanne Tie (Melbourne, VIC, Australia)
- Eric Van Cutsem (Leuven, Belgium)
43O - Preoperative chemotherapy prior to primary tumor resection for colorectal cancer patients with asymptomatic resectable primary lesion and synchronous unresectable liver-limited metastases (RECUT): A prospective, randomized, controlled, multicenter clinical trial
- Qi Lin (Shanghai, Changning, China)
Abstract
Background
Primary tumor resection (PTR) was preferably performed for metastatic colorectal cancer (mCRC) with an asymptomatic resectable primary tumor and synchronous unresectable colorectal liver-limited metastases (CRLMs) with conversion therapy intent.
Methods
This randomized phase III study investigated the superiority of pre-PTR chemotherapy versus upfront PTR for these asymptomatic CRLMs patients. Chemotherapy regimens consisting of either mFOLFOX6 plus cetuximab, mFOLFOX6 plus bevacizumab or mFOLFOX6 alone were assessed according to the RAS genotype and patient affordability. The primary end point was progression-free survival (PFS), and secondary outcomes included overall survival (OS), tumor response, conversion rate to liver metastasis resection, surgical complications and chemotherapy toxicity.
Results
Between June 2012 and June 2018, 320 patients were randomly assigned to undergo pre-PTR chemotherapy (160 patients; arm A) or upfront PTR (160 patients; arm B). The median follow-up time was 36.2 months. Patients in arm A had significantly increased median PFS (10.5 v 9.1 months; hazard ratio = 0.755 [95% CI, 0.60 to 0.95]; P = 0.013) compared with arm B. Patients in arm A also had a significantly better disease control rate (84.4% v 75.0%; P = .037). The median OS (29.4 v 27.2 months; hazard ratio = 0.766 [95% CI, 0.58 to 1.01], P = .058), objective response rate (53.1% v 45.0%; P = .146) and actual resection rate of liver metastases (21.9% v 18.1%; P = .402) were not significantly different. Mild morbidities occurred and no 30-day postoperative mortalities in both arms, the Clavien–Dindo 3-4 complications post PTR did not reach statistical significance (4.5% v 3.8%, P = .759). The observed toxicity of chemotherapy was mostly mild, and there was no significant difference in the overall incidence of predefined grade 3/4 events (42.2% v 40.4%, P = .744).
Conclusions
Pre-PTR chemotherapy improves PFS in the treatment of these asymptomatic CRLMs patients over upfront PTR. Pre-PTR chemotherapy should remain the preferred reference treatment for these eligible patients.
Clinical trial identification
NCT01307878.
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (82072678); Clinical Research Plan of SHDC (No. SHDC2020CR1033B).
Disclosure
All authors have declared no conflicts of interest.
Invited Discussant 43O
- Iain B. Tan (Singapore, Singapore)
Q&A and discussion
- Jeanne Tie (Melbourne, VIC, Australia)
45MO - Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
- Yasutoshi Kuboki (Kashiwa, Japan)
Abstract
Background
Sotorasib (Soto), a KRASG12C inhibitor, showed modest clinical activity as monotherapy in heavily pretreated patients (pts) with KRAS G12C-mutated colorectal cancer (CRC) in the CodeBreaK 100 phase 2 study, with a 9.7% objective response rate (ORR). Early data from the CodeBreaK 101 phase 1b dose exploration (n=8) and expansion (n=18) cohorts showed promising antitumor activity for the combination of Soto and panitumumab (Pmab), an EGFR antibody, in chemorefractory KRAS G12C-mutated metastatic CRC (mCRC). Here, we report results from the fully enrolled dose expansion cohort of 40 pts with refractory mCRC.
Methods
CodeBreaK 101 (NCT04185883) subprotocol H includes dose exploration and expansion in multiple cohorts. Key eligibility criteria for the refractory mCRC cohort included progression on or after prior fluoropyrimidine, oxaliplatin, irinotecan and an anti-angiogenic agent. Primary endpoint is safety. Secondary endpoints include antitumor activity, progression-free survival (PFS), overall survival (OS), and pharmacokinetics (PK).
Results
As of March 25, 2022, 40 pts (75% female, median age 57.5 years) were enrolled and received oral Soto 960 mg daily and Pmab 6 mg/kg IV every 2 weeks. Median prior lines of therapy was 2. Treatment-related adverse events (TRAEs) of any grade occurred in 37 (92.5%) pts. Grade 3 TRAEs occurred in 9 (22.5%) pts; related to Soto and Pmab in 6 (15%) and 8 (20%) pts, respectively. No TRAEs were Grade >3 or resulted in treatment discontinuation. Safety findings were consistent with known profiles of Soto and Pmab. Confirmed ORR was 30% (95% CI: 16.6, 46.5). Disease control rate was 90% (95% CI: 76.3, 97.2). Tumor shrinkage of any magnitude was observed in 35 (87.5%) pts. Soto PK exposures were consistent to those observed in monotherapy studies.
Conclusions
This dataset provides further evidence of safety and tolerability for the combination of Soto and Pmab in heavily pretreated pts with KRAS G12C-mutated mCRC, with 3-fold higher response than previously observed with Soto monotherapy, supporting further development of this combination. Longer follow up data with duration of response, PFS, and OS will be presented.
Clinical trial identification
NCT04185883.
Editorial acknowledgement
Medical writing support was provided by Tim Harrison, PharmD (Amgen Inc.).
Legal entity responsible for the study
Amgen Inc.
Funding
Amgen Inc.
Disclosure
Y. Kuboki: Financial Interests, Institutional, Research Grant: Amgen, Taiho, Astelas, Lilly, Takeda, Daiichi-Sankyo, AstraZeneca, Boehringer Ingelheim, Chugai, Genmab, GlaxoSmithKline, Incyte, Abbie; Financial Interests, Personal, Advisory Role, Consulting fees: Taiho, Takeda, Boehringer Ingelheim, Amgen; Financial Interests, Personal, Speaker’s Bureau: Taiho, Ono, Lilly, Bristol Myers Squibb. R. Yaeger: Financial Interests, Personal, Advisory Board: Pfizer, Natera, Mirati Therapeutics; Financial Interests, Institutional, Invited Speaker: Mirati Therapeutics, Boehringer Ingelheim, Pfizer. M. Fakih: Financial Interests, Institutional, Research Grant: Genentech, Verastem; Financial Interests, Personal, Advisory Role, Consulting fees: AstraZeneca, Bayer Corporation, HalioDX, Incyte Corporation, Mirati, Pfizer, Inc, PsiOxus, Taiho Oncology, Zhuhai Yufan Biotech; Financial Interests, Personal, Speaker’s Bureau: Amgen Inc; Financial Interests, Personal, Invited Speaker: Guardant360; Financial Interests, Personal, Advisory Board: Amgen Inc, Bayer Corporation, GlaxoSmith Kline, Nouscom, Roche/Genentech, Seattle Genetics; Financial Interests, Institutional, Product Samples: Bristol Myers Squibb. J.H. Strickler: Financial Interests, Personal, Advisory Board: SeaGen, AstraZenca, Amgen, Pfizer, Bayer, AbbVie, Natera, Viatris, Inivata, Silverback Therapeutics; Financial Interests, Personal, Other, Consulting: Mereo, GSK, Pionyr Immunotherapeutics; Financial Interests, Institutional, Invited Speaker: SeaGen, Roche Genentech, AbbVie, AstraZeneca, Amgen, AStar D3, Sanofi, Curegenix, Nektar, Leap Therapeutics, Daiichi Sankyo, Erasca, Gossamer Bio, Silverback Therapeutics. T. Masuishi: Financial Interests, Personal, Invited Speaker: Takeda, Chugai, Merck Bio Pharma, Taiho, Bayer, Eli Lilly, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono, Bristol myers squibb; Financial Interests, Institutional, Funding: Daiichi Sankyo, Ono, Novartis, Amgen, Syneos Healthe Clinical, Boehringer-Ingelheim, Pfizer, Cimic Shift Zero, Eli Lilly. E.J. Kim: Financial Interests, Institutional, Research Grant: NGM, Erytech, Fibrogen, Eureka, Merck, BMS, Astellas, Boston Biomedical, AZ, Celgene, Halozyme, Samumed, Epicentrx; Financial Interests, Personal, Advisory Role: Eisai, Taiho, Celgene, Lilly; Financial Interests, Personal, Speaker’s Bureau: Eisai; Financial Interests, Personal, Advisory Board: Lilly. C.M. Bestvina: Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, CVS, Genentech, Jazz, JNJ, Novartis, Pfizer, Regeneron/Sanofi, Seattle Genetics, Takeda; Financial Interests, Personal, Speaker’s Bureau: Merck; Financial Interests, Personal, Other, Travel reimbursement: EMD Serono. C.J. Langer: Financial Interests, Personal, Advisory Role, Honoraria, consulting/advisory role: Bristol Myers Squibb, Genentech/Roche, Lilly/ImClone, AstraZeneca, Merck; Financial Interests, Personal, Advisory Role, Honoraria: Takeda Science Foundation; Financial Interests, Personal, Advisory Role, Consulting/advisory role: Abbott Biotherapeutics, Bayer/Onyx, Clarient, Clovis Oncology, Celgene, Cancer Support Community, ARIAD, Takeda, Pfizer, Novocure, Gilead Sciences; Financial Interests, Institutional, Research Grant: Merck, Advantagene, Clovis Oncology, Celgene, Inovio Pharmaceuticals, Ariad, GlaxoSmithKline, Genentech/Roche, Stem CentRx, Lilly, Trizell. J.C. Krauss: Financial Interests, Institutional, Invited Speaker, Site PI for clinical trial: Sumitomo Dainippon Pharma Oncology, Inc., Novartis Pharmaceuticals Corporation, Amgen, Inc., Merck Sharp & Dohme Res. Labs TO Nsabp Foundation; Financial Interests, Institutional, Invited Speaker, Site PI for clinical Trial: Hutchison Medipharma Limited TO Syneos Health, LLC, Ignyta, Inc. TO Quintiles, Inc; Financial Interests, Institutional, Invited Speaker, Site PI for Clinical Trial: Isofol Medical AB; Financial Interests, Institutional, Invited Speaker, Site PI for a clinical trial: AbbVie, Inc., Bristol Myers Squibb, MedImmune, Pfizer, Daiichi Sankyo Company, Ltd. TO Syneos Health, LLC. S. Puri: Financial Interests, Personal, Advisory Role, Consulting fees: AstraZeneca, G1 Therapeutics. P. Cardona, E.K. Chang, Q. Tran: Financial Interests, Personal, Full or part-time Employment: Amgen Inc; Financial Interests, Personal, Stocks/Shares: Amgen Inc. D.S. Hong: Financial Interests, Personal, Other, Travel, accommodations, expenses: AACR, ASCO, Bayer, Genmab, Gilead, SITC, Telperian; Financial Interests, Personal, Other, Consulting, Speaker, or Advisory Role: AbbVie, Adaptimmune, Alpha Insights, Acuta, Alkermes, Amgen, Aumbiosciences, Axiom, Baxter, Bayer, Boxer Capital, BridgeBio, COR2ed, COG, Cowen, Ecor1, Gennao Bio, Genentech, Gilead, GLG, Group H, Guidepoint, HCW Precision, Immunogen, Infinity, Janssen, Liberium, MedaCorp, Medscape, Numab, Oncologia Brasil, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, RAIN, SeaGen, ST Cube, Takeda, Tavistock, Trieza Therapeutics, Turning Point Therapeutics, WebMD, YingLing Pharma, Ziopharm; Financial Interests, Personal, Ownership Interest, Advisor: Molecular Match; Financial Interests, Personal, Ownership Interest, Founder, Advisor: OncoResponse, Telperian; Financial Interests, Institutional, Research Grant: AbbVie, Adaptimmune, Adlai-Nortye, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Deciphera, Eisai, Eli Lilly, Endeavor, Erasca, F. Hoffmann-LaRoche, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa Kirin, Loxo, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda, TCR2, Teckro, Turning Point Therapeutics, VM Oncology.
46MO - FRESCO-2: A global / multiregional phase III clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer
- Takayuki Yoshino (Kashiwa, Chiba, Japan)
Abstract
Background
Effective treatment options are limited for patients (pts) with refractory metastatic colorectal cancer (mCRC). Fruquintinib (F), a highly selective, potent, oral tyrosine kinase inhibitor of VEGFR-1, -2, and -3 was approved in China in the 3L+ mCRC setting based on results from the FRESCO trial (NCT02314819). FRESCO-2 (NCT04322539) evaluated F in more heavily pretreated pts reflecting current global practices.
Methods
FRESCO-2 was a randomized, double-blind, placebo (P)-controlled, phase 3 MRCT conducted in the US, Europe, Japan & Australia comparing F + best supportive care (BSC) with P + BSC. F or P was given 5 mg PO, QD, 3 weeks on, 1 week off, in 28-day cycles. Key criteria: prior chemotherapy, anti-VEGF therapy, and, if RAS wild type (WT), anti-EGFR therapy; if BRAFV600E mutant (MT) or MSI-H, ≥1 targeted regimen; and prior exposure to trifluridine/tipiracil (T) and/or regorafenib (R). Pts were randomized 2:1 to F + BSC or P + BSC and stratified by: prior T, R, or both; RAS status (WT, MT); and duration of metastatic disease (≤18, >18 months [m]). The primary endpoint was overall survival (OS). Key secondary endpoints were progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Final OS analysis was after 480 OS events.
Results
From 02Sep2020 to 14Dec2021, 691 pts were randomized; F:461 vs P:230. Baseline characteristics were balanced. F significantly improved OS (median: 7.4 m vs 4.8 m P; HR=0.66 [95%CI: 0.55, 0.80]; p<0.001) & PFS (median: 3.7 m vs 1.8 m P; HR=0.32 [95% CI: 0.27, 0.39]; p<0.001). Median duration of follow-up was 11.3 m F vs 11.2 m P. Subsequent anti-cancer therapies were 29.4% F vs 34.3% P. DCR was 55.5% F vs 16.1% P & ORR was 1.5% F vs 0% P. Grade ≥3 treatment-emergent adverse events were 62.7% F vs 50.4% P; those occurring in ≥5% on F were hypertension (13.6% vs 0.9% P), asthenia (7.7% vs 3.9% P), & hand-foot syndrome (6.4% vs 0% P).
Conclusions
F had a significant and clinically meaningful improvement in OS in pts with refractory mCRC. F was well tolerated with a safety profile consistent with the established profile for F monotherapy. FRESCO-2 results are consistent with FRESCO and should support a new treatment option in refractory mCRC.
Clinical trial identification
NCT04322539.
Editorial acknowledgement
Editorial support in the preparation of this abstract was provided by Team 9 Science, a Vaniam Group agency, funded by HUTCHMED International.
Legal entity responsible for the study
Hutchison Medipharma Limited.
Funding
Hutchison Medipharma Limited.
Disclosure
T. Yoshino: Financial Interests, Personal, Invited Speaker: Chugai, Merck Biopharma, Bayer, Ono, MSD; Financial Interests, Institutional, Invited Speaker: Ono, Sanofi, Daiichi Sankyo, Chugai, Pfizer; Financial Interests, Institutional, Research Grant: Taiho, MSD, Ono, Amgen, Genomedia, Sysmex, Daiichi Sankyo, Chugai, Boehringer Ingelheim. N.A. Dasari: Financial Interests, Institutional, Research Grant: HUTCHMED, Guardant Health, Natera Inc, AAA/Novartis, Eisai; Financial Interests, Personal, Advisory Board: HUTCHMED, Personalis Inc, Crinetics, Voluntis; Financial Interests, Personal, Research Grant: Crinetics. S. Lonardi: Financial Interests, Personal, Advisory Board: Amgen, Merck Serono, Lilly, Servier, AstraZeneca, MSD, Incyte, Daiichi-Sankyo, Bristol Myers Squibb, Mirati; Financial Interests, Personal, Invited Speaker: Pierre-Fabre, GlaxoSmithKline, Roche; Financial Interests, Institutional, Invited Speaker: Amgen, Merck Serono, Bayer, Roche, Lilly, AstraZeneca, Bristol Myers Squibb. R. Garcia-Carbonero: Financial Interests, Personal, Advisory Board: AAA, Advanz Pharma, Amgen, Bayer, BMS, HMP, Ipsen, Merck, Midatech, MSD, Novartis, Pharma Mar, Pierre Fabre, Servier; Financial Interests, Institutional, Research Grant: BMS, MSD, Pfizer; Non-Financial Interests, Personal, Leadership Role, Global PI of investigator-initiated clinical trials (AXINET, NICENEC, PEMBROLA): BMS, MSD, Pfizer; Other, Personal, Other, Honoraria received by spouse for advisory board or invited speaker roles: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Genomica, LILLY, MSD, Merck, Novartis, Pfizer, PharmaMar, Roche, Sanofi, Servier, Takeda. M.E. Elez Fernandez: Financial Interests, Personal, Advisory Board: Hoffman La - Roche, Servier, Amgen, Merck Serono, Sanofi, Bayer, Pierre Fabre, MSD; Financial Interests, Personal, Invited Speaker: Organon, Novartis; Financial Interests, Institutional, Funding: Hoffmann-La Roche Ltd., Sanofi Aventis Recherche & Développement, Amgen Inc., Boehringer Ingelheim, Novartis Farmacéutica SA, Bristol Myers Squibb International Corporation, BeiGene, HalioDX SAS, Janssen-Cilag SA, Merck Health KGAA, Merck Sharp & Dohme de España SA, PharmaMar SA, Servier, Taiho Pharma USA Inc, Hutchison MediPharma International, Menarini, Merus NV, Pfizer, Mirati, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, Celgene International SARL, Debiopharm International SA, Genentech Inc, MedImmune; Non-Financial Interests, Personal, Other, Coordinator of the SEOM +MIR Section of Residents and Young Assistants: Sociedad Española de Oncología Médica (SEOM); Non-Financial Interests, Personal, Other, Speaker of the ESMO Academy: European Society for Medical Oncology (ESMO); Non-Financial Interests, Personal, Other, Volunteer member of the ASCO Annual Meeting Scientific Program Committee: Developmental Therapeutics – Immunotherapy: American Society of Clinical Oncology (ASCO); Other, Personal, Other, Travel, accommodations, expenses.: Roche, Merck Serono, Sanofi, Amgen, Array BioPharma, Servier, Bristol Myers Squibb. A. Sobrero: Financial Interests, Personal, Advisory Board: servier, bms, msd, incyte; Financial Interests, Personal, Invited Speaker: bayer, pierre fabre, merck, amgen, sanofi; Financial Interests, Personal, Stocks/Shares: bayer. J.C. Yao: Financial Interests, Personal, Advisory Board: Ipsen, Chiasma Pharma, Amgen, Critics; Financial Interests, Personal, Other, Consultancy: Hutchison Medi Pharma; Financial Interests, Personal, Invited Speaker: Medscape; Financial Interests, Institutional, Invited Speaker: Advanced Accelerator Applications International, Novartis. P. García Alfonso: Financial Interests, Institutional, Research Grant: Roche, Lilly, Sanofi, Merck, Amgen, Servier, Piere Fabre; Financial Interests, Personal, Advisory Role, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Roche, Lilly, Sanofi, Merck, Amgen, Servier, Piere Fabre; Financial Interests, Personal, Other, Travel Support: Roche, Lilly, Sanofi, Merck, Amgen, Servier, Pierre Fabre; Financial Interests, Personal, Advisory Board: Roche, Lilly, Sanofi, Merck, Amgen, Servier, Pierre Fabre. A. Sartore Bianchi: Financial Interests, Personal, Invited Speaker: Amgen, Bayer; Financial Interests, Personal, Advisory Board: Amgen, Bayer, Novartis, Servier. J. Tomasek: Financial Interests, Personal, Advisory Role: Servier, Bristol Myers Squibb, Amgen, Pierre Fabre, Merck; Financial Interests, Personal, Invited Speaker: Servier, Bristol Myers Squibb, Amgen, Pierre Fabre, Merck; Financial Interests, Personal, Other, Travel Support: Merck, Novartis. G. Chong: Financial Interests, Personal and Institutional, Research Grant: HUTCHMED, BMS, Isofol, Regeneron, Pharmacyclics, Incyte, Bayer, Merck Serono, AstraZeneca; Financial Interests, Personal and Institutional, Invited Speaker: BMS. Z. Yang: Financial Interests, Personal, Other, Employment: HUTCHMED. W. Schelman: Financial Interests, Personal, Other, Employment: HUTCHMED. M. Kania: Financial Interests, Personal, Other, Employment: HUTCHMED; Financial Interests, Personal, Stocks/Shares: HTUCHMED; Financial Interests, Personal, Leadership Role: HUTCHMED. J. Tabernero: Financial Interests, Personal, Advisory Board, scientific consultancy role: Orion Biotechnology, Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daichii Sankyo, F. Hoffmann-La Roche Ltd., Genentech Inc., HalioDX SAS, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics, TheraMyc, Hutchinson MediPharma International, Scandion Oncology, Ona Therapeutics, Sotio Biotech, Inspirna Inc, Scorpion Therapeutics; Financial Interests, Personal, Invited Speaker, educational collaboration: Medscape Education, Physicians Education Resource (PER), PeerView Institute for Medical Education, Imedex / HMP; Financial Interests, Personal, Invited Speaker, educacional collaboration: MJH Life Sciences; Financial Interests, Personal, Other, Stocks: Oniria Therapeuics; Financial Interests, Institutional, Research Grant, ACRCelerate: Colorectal Cancer Stratified: Fundación Científica de la Asociación Española Contra el Cáncer; Financial Interests, Institutional, Research Grant, OPTIMISTICC: Opportunity to Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer: Cancer Research UK; Financial Interests, Institutional, Funding, Clinical Trials & Research: Amgen Inc, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb International Corporation, Celgene International SARL, Debiopharm International SA, F. Hoffmann-La Roche Ltd., Genentech Inc, Janssen-Cilag International NV, Merck Health KGAA, Merck, Sharp & Dohme de España, SA, Novartis Farmacéutica SA, PharmaMar SA, Sanofi-Aventis Recherche & Développement, Servier, Taiho Pharma USA, Inc, BeiGene, Boehringer Ingelheim, HalioDX SAS, Hutchinson Medipharma, MedImmune, Menarini, Merus N V, Pfizer, Mirati; Non-Financial Interests, Personal, Invited Speaker, Board of Directors: Cancer Core Europe, Spanish Association Against Cancer -AECC; Non-Financial Interests, Personal, Invited Speaker, General Assembly: Horizon Europe Cancer Mission; Non-Financial Interests, Personal, Leadership Role, External Scientific Committee: Institute for Health Research INCLIVA – Clinical Hospital of Valencia, IdiSNA –Universidad de Navarra; Non-Financial Interests, Personal, Leadership Role, Scientific Advisory Board: Spanish National Cancer Research Centre (CNIO); Non-Financial Interests, Personal, Advisory Role, International Scientific Evaluation Committee: Bosch Health Campus (BHC); Non-Financial Interests, Personal, Advisory Role, Review Board: National Decade Against Cancer (NCT) - German Consortium for Translational Cancer Research (DKTK); Non-Financial Interests, Personal, Advisory Role, Scientific Advisory Board: Karolinska Comprehensive Cancer Centre; Non-Financial Interests, Personal, Advisory Role, International Review Committee (IRC): Oncode Institute; Non-Financial Interests, Personal, Advisory Role, Scientific Advisory Board (SAB): Oslo University Hospital Comprehensive Cancer Centre (OUH CCC); Non-Financial Interests, Personal, Leadership Role, Governance Advisory Committee: European Organization for Research and Treatment of Cancer -EORTC; Non-Financial Interests, Personal, Leadership Role, Vice Chairman: World Innovative Networking (WIN) Consortium in Personalized Cancer Medicine; Non-Financial Interests, Personal, Other, Coordinating PI & Steering Committee Member. Clinical Trials & Research: Array Biopharma Inc., AstraZeneca Pharmaceutical LP, Boehringer Ingelheim, MedImmune, Menarini, Merck Healthcare KGAA, Merck, Sharp & Dohme de España SA, Pfizer, Servier; Non-Financial Interests, Personal, Principal Investigator, Clinical Trials & Research: Array Biopharma Inc., AstraZeneca Pharmaceutics LP, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb International Corporation, Celgene International SARL, Debiopharm International SA, F. Hoffmann-La Roche Ltd., Genentech Inc., HalioDX SAS, Hutchinson Medipharma, Janssen-Cilag International NV, MedImmune, Merck Healthcare KGAA, Menarini, Merck, Sharp & Dohme de España SA, Merus NV, Mirati, Novartis Farmacéutica SA, Pfizer, Sanofi-Aventis Recherche & Développement, Servier, Taiho Pharma USA Inc; Non-Financial Interests, Personal, Other, Steering Committee Member. Clinical Trials & Research: Debiopharm International SA, F. Hoffmann-La Roche Ltd., Genentech Inc., HalioDX SAS, Hutchinson Medipharma, Janssen-Cilag International NV, Merus NV, Taiho Pharma USA Inc; Non-Financial Interests, Personal, Other, Coordinating PI. Clinical Trials & Research: Mirati; Non-Financial Interests, Personal, Member: AACR, ASCO, EACR, EORTC, SEOM; Other, Personal, Other, President: Oncology Master Plan – Catalonia Department of Health; Other, Personal, Other, Advisory Committee: Advisory Committee on Pharmaceutical Provision Financing under the Spanish National Health System. C. Eng: Financial Interests, Institutional, Research Grant: Pfizer, Elevar, Merck, Gritstone; Financial Interests, Personal, Advisory Role: Bayer, GSK, Halio Dx, Boston Scientific. T. Satoh: Financial Interests, Personal, Invited Speaker, invited speaker and advisory: Ono Pharmaceutical, Daiichi-Sankyo; Financial Interests, Personal, Invited Speaker, Invited speaer and adovisory: Bristol Myers; Financial Interests, Personal, Invited Speaker, Invited speaker and advisory: Elli-Lilly, Yakult-HOnsha; Financial Interests, Personal, Invited Speaker: Chugai Pharmazeutical, Merck-Biopharm, Takeda, Taiho; Financial Interests, Personal, Advisory Board: Takara-Bio; Financial Interests, Institutional, Invited Speaker: Merck-Biopharm, Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker, Research Grant and Endosed Department: Ono Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha; Financial Interests, Institutional, Invited Speaker, Research Grant: Elli-Lilly, Daiichi-Sankyo, Parexell, Giliad, Taiho, Hutch-Med. All other authors have declared no conflicts of interest.
Invited Discussant 45MO and 46MO
- Jeanne Tie (Melbourne, VIC, Australia)
Q&A and discussion
- Jeanne Tie (Melbourne, VIC, Australia)